Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple score shorten blood thinner use after a heart attack?

NCT ID NCT06216821

Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a risk score (OPT-CAD) can safely guide how long heart attack patients need to take two blood thinners after getting a stent. About 3,490 participants will either follow standard 12-month dual therapy or have their therapy reduced to one blood thinner earlier (1 month for low-risk, 3 months for higher-risk). The goal is to see if this personalized approach lowers the combined risk of death, heart attack, stroke, stent clots, and major bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) with de-escalation to a single P2Y12 inhibitor
What this could lead to
If successful, this could provide a personalized approach to shorten the time patients need to take two blood thinners after a heart attack, reducing bleeding risk while still preventing clots.
What could go wrong
This is a single-country, open-label trial, so results may not apply globally. The risk score is new and may not accurately predict outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,490 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients with ages of 18-80 years; 2. Patients with clinically diagnosed ACS who have undergone at least one DES implantation; 3. Individuals capable of completing the OPT-CAD scoring calculation; 4. Researchers assessing that participants can tolerate at least a 12-month duration of DAPT therapy; 5. Written informed consent provided. Exclusion Criteria: 1. Left main coronary artery lesion PCI; 2. Allergy to study drugs such as aspirin, clopidogrel, or ticagrelor; 3. Meeting 1 major or 2 minor criteria for high bleeding risk according to the ARC-HBR criteria; 4. Anticipated need for revascularization or surgical intervention within 12 months; 5. Severe ischemia or hemorrhage events during the current hospitalization; 6. Life expectancy of other serious diseases is less than 1 year; 7. Pregnant or women of childbearing age who intend to conceive within 1 year; 8. Participation in other clinical trials while still under observation; 9. Researchers considering ineligibility for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital of Northern Theater Command

    RECRUITING

    Shenyang, Liaoning, 110016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.